Nova’s hepatitis B disease (HBV) model accounts for the virus pathophysiology, including viral replication within hepatocytes and antiviral immune response in chronically infected patients. Nova’s chronic hepatitis B model for exploring and predicting efficacy for novel HBV treatments.
Model description (HBV)
Drugs that can be tested
Populations of interest
Possible clinical endpoints
Early insights to optimize your trial design
Combination of treatments
Get your questions answered by downloading the free pdf and learn more about your therapeutic area of interest!